ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

TIL Instill Bio Inc

11.44
-0.06 (-0.52%)
After Hours
Last Updated: 16:00:01
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,407
Bid Price 11.00
Ask Price 11.88
News -
Day High 11.47

Low
6.07

52 Week Range

High
13.038

Day Low 11.16
Company Name Stock Ticker Symbol Market Type
Instill Bio Inc TIL NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.06 -0.52% 11.44 16:00:01
Open Price Low Price High Price Close Price Prev Close
11.47 11.16 11.47 11.44 11.50
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
102 1,407 $ 11.39 $ 16,023 - 6.07 - 13.038
Last Trade Time Type Quantity Stock Price Currency
16:06:47 1 $ 11.09 USD

Instill Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
74.41M 6.50M - 0 -156.09M -24.00 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Instill Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No TIL Message Board. Create One! See More Posts on TIL Message Board See More Message Board Posts

Historical TIL Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.7712.499911.2211.876,411-0.33-2.80%
1 Month10.6012.499910.1511.2111,2690.847.92%
3 Months11.6812.9810.1511.4312,891-0.24-2.05%
6 Months6.98412.986.077.4493,0434.4663.80%
1 Year12.70413.0386.079.25305,975-1.26-9.95%
3 Years369.192473.606.07104.88504,055-357.75-96.90%
5 Years540.00589.806.07118.23496,622-528.56-97.88%

Instill Bio Description

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma.

Your Recent History

Delayed Upgrade Clock